Form 4 for MBX MBX Biosciences, Inc.
Accepted 2025-10-28 00:00:00 ET · period of report 2025-10-24 · accession 0001193125-25-252404 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-28 | 2025-10-24 | MBX | Hawryluk P. Kent | Pres, CEO, Dir | M - OptEx | $3.25 | +182.9K | 664.3K | +38% | +$594.3K |
| D | 2025-10-28 | 2025-10-24 | MBX | Hawryluk P. Kent | Pres, CEO, Dir | M - OptEx | $0.00 | -182.9K | 129.7K | -59% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-24 | M | A | 182,859 | $3.25 | 664,256 | D | — | — | |
| 2 | Derivative | Stock option (right to buy) | 2025-10-24 | M | D | 182,859 | $0.00 | 129,708 | D | $3.25 · 2022-11-07 to 2032-11-06 | 182,859 Common Stock | (F2) 1/48th of the shares underlying this option vest in substantially equal monthly installments on each monthly anniversary of November 7, 2022, subject to the Reporting Person's continued service on each such vesting date, until the option vests in full on November 7, 2026. The shares underlying this option became exercisable in full on November 7, 2022, pursuant to an early-exercise provision, subject to an Issuer right of repurchase. |